How Pig Organs, Bioprinted Tissue and Stem Cells Could End Transplant Waitlists
Xenotransplantation, 3D bioprinting, and stem cell therapies are converging to solve the global organ shortage crisis.
20 articles
Xenotransplantation, 3D bioprinting, and stem cell therapies are converging to solve the global organ shortage crisis.
A novel dual CAR T-cell approach eliminated blocking antibodies in highly sensitized patients, enabling kidney transplants previously considered impossible.
LyGenesis wins funding to develop immune tolerance for pancreatic islet transplants, using its novel lymph node organ-growing platform.
United Therapeutics wins FDA approval for LungFX, a device that keeps donor lungs viable outside the body for transplant reassessment.
A new perspective outlines how stem cells, bioprinted organs, and cross-species genes could replace — not just repair — aging biology.
Sana Biotechnology's hypoimmune cell therapy may eliminate the need for lifelong immunosuppression in type 1 diabetes transplants.
Tregzi slashes chronic graft-versus-host disease rates from 44% to 12.6%, offering new hope for stem cell transplant patients.
A UC Berkeley spinout is developing a one-time gene therapy using transposons to sustain GLP-1 activity — potentially replacing daily weight loss drugs.
A randomized trial found hypothermic oxygenated perfusion slashed early graft failure rates from 37% to 20% in liver transplant patients.
JCR Pharmaceuticals shows its JUST-AAV platform can cross the blood-brain barrier, extending survival in neurological disease mouse models.
A 732,000-patient study finds both pre-existing and new-onset diabetes sharply increase 10-year mortality across four major transplanted organs.
Scarlet Therapeutics grows universal red blood cells that survive as long as donated ones, opening a path to engineered therapeutic blood.
Sana Biotechnology and Mayo Clinic are advancing SC451, a cell therapy that may restore natural insulin production without immunosuppression.
NADMED funds groundbreaking research on metabolic assessment of donor organs, advancing redox biology toward real-world longevity medicine.
Revolutionary CRISPR technique bypasses lab manufacturing by programming immune cells to fight cancer directly in the body.
Redesigned immunotherapy injected into one tumor triggered complete cancer remission in 2 of 12 patients, with untreated tumors also disappearing.
Scribe Therapeutics reports a one-time epigenetic therapy slashed LDL cholesterol up to 68% for nearly two years in primates.
Tregzi, a personalized T cell therapy, wins FDA approval to reduce dangerous immune complications in blood cancer stem cell transplant patients.
Rokit Healthcare gains clinical approval to begin human trials using bioprinted omentum patches to regenerate damaged kidneys.
Next-gen CAR-T approaches skip the lab and engineer immune cells directly inside the body, potentially making cancer therapy faster and cheaper.